An FDA advisory committee yesterday voted 10 to 5 to recommend approving Johnson & Johnson's (JNJ) canagliflozin treatment for Type 2 diabetes, although several of the panelists expressed concerns about its cardiovascular risks and its use for patients with moderate kidney disease. If authorized, analysts have forecast that canagliflozin could generate annual sales of $667M by 2016.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Benzinga.com (Mon, 1:57PM)
at Nasdaq.com (Feb 19, 2015)
at Nasdaq.com (Feb 17, 2015)
at Nasdaq.com (Feb 10, 2015)
at Investor's Business Daily (Jan 20, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs